Research Areas

Forms two stand-alone business units that are intended to leverage the company’s intellectual property and proprietary expertise.

Five-year collaboration to analyze genomic information across large patient samples.

Companies sign research collaboration and license agreement for the discovery and development of TLR-9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease.

Developer of antibody fragment therapeutics recently announced the spin-out of its small-molecule inhibitor programs.

With the acquisition, MediGene will diversify and broaden its drug pipeline with several drug candidates to treat cancer and auto¬immune diseases.

Entered into an agreement to acquire AnorMED Inc., a Canadian-based biopharmaceutical company with a late-stage Phase III hematology-oncology product, Mozobil

Announced the acquisition of Nura Inc., a company developing treatments for pain and other central nervous system disorders.

ChemoCentryx announced it completed $17.7 million in Series C financing.

Market has more than doubled in the last five years—jumping from $25 billion in 2001 to $51 billion in 2005—making it the scientific trump card of the pharmaceutical industry.

The widespread use of protein chips has largely been limited by the need for large-scale protein purification